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Primary sclerosing cholangitis (PSC) is a chronic liver disease of unknown aeti-
ology affecting extrahepatic and/or intrahepatic bile ducts causing its inflamma-
tion and fibrosis with most frequent consequences including biliary cirrhosis and 
liver failure. The incidence of PSC in children and adolescents is 0.2 per 100,000 
children per year, when in adults the reported incidence is higher and equals 0.5 
to 1 in 100,000 individuals per year. PSC is more common among men and boys. 
The diagnosis is usually established in the second decade of life in the paediatric 
population with the mean age of diagnosis of 13.8 years. Many studies point out a 
strong correlation between IBD and PSC, especially ulcerative colitis. The preva-
lence of IBD among children with PSC diagnosis varies from 60 to 99%; however, 
the incidence of PSC is about 12% in patients with ulcerative colitis and fluctuates 
about 2–5% in Crohn’s disease diagnosed patients. Clinical symptoms are present 
in approximately half of cases and they are unspecific in many of them. Elevated 
liver enzymes and biochemical markers of cholestasis are sometimes the only signs 
of PSC. Gold standard for PSC diagnosis is magnetic resonance cholangiopancrea-
tography (MRCP) as a non-invasive procedure comparing to endoscopic retrograde 
cholangiopancreatography (ERCP) which is also used in some cases. The aim of the 
study was to review the risk factors, clinical symptoms, diagnostic methods and 
treatment of paediatric patients with primary sclerosing cholangitis.
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Primary sclerosing cholangitis (PSC) is a chronic liver disease of unknown aeti-
ology affecting extrahepatic and/or intrahepatic bile ducts causing its inflamma-
tion and fibrosis with most frequent consequences including biliary cirrhosis and 
liver failure. The incidence of PSC in children and adolescents is 0.2 per 100,000 
children per year when in adults the reported incidence is higher and equals 0.5 to 
1 in 100,000 individuals per year. Several studies indicate the incidence of primary 
sclerosing cholangitis is increasing. A similar increase has been seen in most auto-
immune diseases. PSC is more common among men and boys. The diagnosis is 
usually established in the second decade of life in the paediatric population with the 
mean age of diagnosis of 13.8 years [1–9].
Many studies point out a strong correlation between IBD and PSC, especially 
ulcerative colitis. The prevalence of IBD among children with PSC diagnosis varies 
from 60 to 99%, however the incidence of PSC is about 12% in patients with 
ulcerative colitis and fluctuates about 2 to 5% in Crohn’s disease diagnosed patients. 
In children, the diagnosis of IBD generally precedes the diagnosis of PSC [10–15].
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1. Aetiology
The pathogenesis of PSC is unknown, but a number of mechanistic theories have 
been proposed. Despite the lack of scientifically proven aetiological factors, many 
components can be responsible for the PSC development.
1.1 Genetic background
Genetic background including an impact of HLA-A1, B8, DR3 haplotypes are 
one of the suspects as the diagnosis is made at a young age and family occurrence 
has been reported. Genome-wide comparisons of the frequency of genetic variants 
have provided a means of dissecting genetic risk in the many human diseases pri-
mary sclerosing cholangitis included. In the pathogenesis of PSC can play the role 
the presence of more non-HLA genes related to immunity and/or bile homeostasis. 
However most PSC genes appear to relate to adaptive immune reactions. There 
are limited genetic links between IBD and PSC. The HLA class 1 (expressed on all 
cells) and HLA class II (expressed on antigen- presenting cells) present potentially 
antigenic peptides derived from intra- and extracellular sources, to the T cell recep-
tor (TCR) on CD* and CD4 T cells. But the antigenic peptides are unknown. Data 
suggest the presence of PSC specific TCR in the livers of patients. The predominant 
cell type in the portal inflammatory infiltrate in liver patients with primary scle-
rosing cholangitis is the T cell. It is suggested that there is cross-reaction between 
cholangiocytes and T-cells. Some of scientists believe that genes as PRDX5, TGR5, 
PSMG1, NFKB1 may play a role in innate immune reactions [11, 16–18].
1.2 Bile acids toxicity
The concentric fibrosis around the bile ducts in PSC is found in a variety of 
conditions and likely represents a final pathway for bile ducts injury. Defects of 
mechanisms protecting against bile acid toxicity can be a factor playing an impor-
tant role in PSC development. The biliary epithelium shows an activated phenotype 
in PSC, including an expansion of the peribiliary gland system [19–21].
1.3 Autoimmunologic factors
What is more, certain autoimmune reactions in genetically susceptible individu-
als seem to play an important role as well. The presence of non-specific autoan-
tibodies such as ANA, ANCA (in >80% of patients) and anti-SMA (in >60% of 
patients) together with autoimmune diseases such as autoimmune hepatitis (overlap 
syndrome PSC/AIH in 25–35%), rheumatoid arthritis, autoimmune thyroiditis 
or type 1 diabetes mellitus suggests that PSC can be described as an autoimmune 
disease. However its prevalence among men (2:1) and the lack of response to immu-
nosuppressive therapy contributed to the concept of PSC being rather an immune-
mediated disease. PSC with high immunoglobulin 4 (IgG4) levels and autoimmune 
hepatitis overlap syndrome have been described. But the lack of the efficacy of 
immunosuppressive treatment despite isolated autoimmune aetiology [11, 22–25].
1.4 Role of microbiota
The predominant coexistence of PSC and IBD led to a theory that dysregulation 
of gut microbiota in IBD patients causes liver T-cell activation provoking an inflam-
matory response in bile ducts. There is increasing appreciation of the co-metabolic 
functions of the gut microbiota in the bile homeostasis. The composition of the gut 
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microbiota in PSC has been described using sequencing technologies. However, data 
from other diseases suggests that reduced bacterial diversity occurs prior to and 
independent from clinical manifestations [26–29].
2. Clinical picture
Clinical symptoms are present in approximately half of cases and they are 
unspecific in many of them. Most frequently patients complain of abdominal pain, 
fatigue and/or abdominal pain. Malaise, jaundice, splenomegaly or pruritus are 
reported less often. Elevated liver enzymes and biochemical markers of cholestasis 
are sometimes the only signs of PSC. The diagnosis of PSC may precede that of IBD, 
which may even present after liver transplantation for PSC. PSC may present in an 
IBD patients even after colectomy. Multiple gallbladder abnormalities in the course 
of primary sclerosing cholangitis including: dilatation (15%), gallstones (25%), 
cholecystitis, hydrops, polyps (4–6%), carcinoma (2.5–3.5%) are observed more 
often in patients [2, 8, 17, 22, 29, 30].
2.1 Forms of PSC
1. Classical large-duct PSC.
2. Small-duct PSC. A diagnosis of small-duct PSC is made upon histological 
findings characteristic of PSC and clinical and biochemical abnormalities 
suggestive of PSC. The HLA associations with IBD in small-duct PSC resemble 
those of large-duct PSC and suggest shared aetiologies between large-duct PSC 
and small -duct PSC in the presence of IBD.
3. PSC with high IgG4. PSC patients with elevated IgG4 are less responsive and 
data suggest they may progress more rapidly than other PSC patients. IgG4 
may be involved in the pathogenesis of autoimmune cholangitis and clinical 
response upon treatment with the anti-CD20 antibody (rituximab).
4. PSC-AIH overlap syndrome. Biochemical and histological features of autoim-
mune hepatitis are apparent in 7–14% of patients with PSC. Elevated trans-
aminases and IgG may indicate autoimmune hepatitis, but may be elevated as a 
part of the biliary disease.
5. PSC with cholangiocarcinoma.
3. Diagnostics
The diagnosis is based on laboratory and imaging results as well as on elimina-
tion of other than PSC cholestatic diseases. When it comes to laboratory results 
among children, gamma-glutamyltransferase (GGT) is more specific cholestatic 
marker than alkaline phosphatase (ALP) as ALP levels tend to fluctuate during 
bone growth. Even though ultrasound (USG) is a cheap and simple way to visualise 
liver pathology, bile ducts abnormalities characteristic of PSC might not be visible. 
Gold standard for PSC diagnosis is magnetic resonance cholangiopancreatography 
(MRCP) with acceptable sensitivity and specificity as a non-invasive procedure 
comparing to endoscopic retrograde cholangiopancreatography (ERCP) which is 
also used in some cases. As typical cholangiographic changes define the diagnosis 
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of PSC, prognostic scoring system. To diagnose small duct PSC which is a type of 
PSC affecting intrahepatic ducts only, as well as to confirm the presence of PSC/
AIH overlap syndrome it is necessary to perform liver histology. In recent years, 
there has been interest in the development of noninvasive tests of liver fibrosis for 
stratification and prognosis in PSC. Serum tests of liver fibrosis reflect fibrogenesis 
(APRI, Fib4 score). Liver stiffness measurement by transient elastography has been 
validated for the assessment of liver fibrosis in the liver diseases. Elastography in 
patients with PSC well correlate with the degree of fibrosis, performing best at the 
extremes of histological stage [5, 11, 31–34].
3.1 Differential diagnosis of PSC
1. Choledocholithiasis.
2. Congenital abnormalities of bile duct.
3. Cholangiocarcinoma without PSC.
4. Traumatic/ischemic changes in bile ducts.
5. HIV infection.
6. Infestation (ascaris, lambliosis)
7. Sarcoidosis.
8. Pyogenic cholangitis
3.2 Patients with PSC need control every 6 months
• Clinical review
• Serum liver tests
• Tumour marker: Ca 19-9, AFP
• Ultrasonography examination
• MRI/MRC if cirrhosis
4. Prognosis and complications
PSC is a progressive disease where bile ducts fibrosis lead to cirrhosis and liver 
failure. PSC has a highly variable natural history. Asymptomatic patients have 
been shown to have a better prognosis than patients with symptoms at diagnosis. 
Comparing to adults, PSC in children seems milder, yet 15–45% of paediatric 
patients will require liver transplantation within 6–12 years after the diagnosis. 
The increased risk of biliary cancer and colorectal cancer in PSC is firmly estab-
lished and of major clinical importance. The risk of cholangiocarcinoma (CCA) 
is about 160 times higher than in the general population. In spite of that, only 1% 
of patients experience this serious complication. In a multi-centre study of 7000 
PSC patients hepatobiliary malignancy was diagnosed in 10.9%. Up to 50% of 
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cholangiocarcinoma are detected within a year of PSC diagnosis. Unfortunately, 
PSC diagnosed children may also develop other types of cancers such as gallbladder, 
colon or hepatocellular cancer. In the majority of cases, the early stages of cholan-
giocarcinoma are asymptomatic. Sometimes are observed abdominal pain, weight 
loss, increasing jaundice. Diagnosis of cholangiocarcinoma is based on tumour 
marker Ca19-9, imaging modalities, biliary brush cytology. The indication for liver 
transplantation in patients with dysplasia and no signs of cholangiocarcinoma 
remain controversial. Presence of dysplasia of any grade has been reported in 83% 
of explant livers with PSC-cholangiocarcinoma and 36% without cholangiocar-
cinoma. MRI and CT may visualise early features of cholangiocarcinoma in PSC 
but difficulties in distinguishing inflammatory, bening and malignant lesions lead 
to suboptimal diagnostic accuracy. Combined MRI/cholangioMRI has the highest 
sensitivity and specificity and is preferred for detection of small focus cholangio-
carcinoma. Liver transplantation or surgery with complete resection is the only 
treatments with curative intent for cholangiocarcinoma. Liver transplantation with 
neoadjuvant therapy (external beam radiotherapy, endoluminal brachytherapy, 
chemotherapy) can be considered in patients with unresectable, perihilar early 
stage. Systemic chemotherapy remains the palliative treatment for patients not 
eligible for surgery. Other palliative treatment strategies include endoscopic stent-
ing and photodynamic therapy.
PSC-IBD whether considered UC or Crohn’s disease is almost universally colonic 
(usually a pancolitis) with a right-sided predominance, backwash ileitis and rectal 
sparing. The risk of colorectal cancer is fivefold higher than in IBD without PSC 
and may occur at any time from diagnosis. Colonoscopy should be performed in 
patients with PSC regularly from the moment of diagnosis. Chromoendoscopy is 
being increasingly recommended to facilitate detection of flat lesions with dys-
plasia. Four quadrant biopsies from all colonic segments and the terminal ileum 
should be performed. Hepatocellular and pancreatic cancer also occur in patients 
with PSC, but frequencies are lower than in cirrhosis liver from other causes. 
Currently there are no established prognostic tools that reliably estimate prognosis 
of the patients [2, 35–46].
5. Treatment
Effective ways of PSC treatment are still lacking. Immunosuppressive medica-
tions did not show any benefits, while oral vancomycin therapy might be an option 
although more data is required. Symptomatic treatment of PSC also consists of 
supplementing the deficiencies of fat-soluble vitamins, preventing the development 
of osteoporosis and combating chronic itching: by using additional cholestyramine 
at a dose of 6–8 g/24 h and/or rifampicin. For patients refractory to the above-
mentioned treatment, oral naloxone therapy (50 mg/24 h) may be effective.
5.1 Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) is commonly used and has been proved to reduce 
GTP and AP levels which are both good prognostic factors improving patients’ 
survival. However, UDCA treatment did not result in improved outcomes compared 
to no intervention. New therapeutic applications have been derived from this 
research in the form of norUDCA, to enhance general resistance to bile acid induced 
biliary injury. NorUDCA is slightly amidated in the liver, it is secreted into the bile 
in both unbound and glucuronic acid form. The biliary-hepatic flow of unbound 
norUDCA induces excessive secretion of bile rich in bicarbonate. Studies in mouse 
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models have shown that the drug is less toxic, more effectively prevents peripheral 
fibrosis, proliferation of hepatocytes and cholangiocytes, reduces the content of 
hydroxyproline and infiltrating immune cells. In addition, it improves cholestasis 
parameters [6, 31, 47–48].
5.2 Vankomycin
Antibiotics, particularly vancomycin, may have a positive effect on PSC either via 
direct effects on the microbiome or via host-mediated mechanisms. In addition van-
comycin has possible immunomodulatory and anti-inflammatory mechanisms, But 
there is not currently sufficient evidence to support treatment recommendations. 
Further research is needed to establish if vancomycin is a PSC treatment [48–50].
5.3 ERCP
Bile duct strictures are possible complications in the course of the disease that 
can be treated with prothesis during ERCP. The generally accepted arbitrary defini-
tion is stenosis of <1.5 mm in the common bile duct or <1 mmin the hepatic duct 
within 2 cm of the hilum. The incidence of complications associated with ERCP in 
patients with PSC is 4–18% [44, 46, 48].
5.4 Liver transplantation
Liver transplantation is a life-saving procedure with generally good outcomes, 
however, up to 16% of paediatric patients are affected by recurrent primary scleros-
ing cholangitis (rPSC) after transplantation. The indications for liver transplanta-
tion in PSC are similar to other liver diseases and transplanted with a qualifying 
MELD/PELD score in a patient with cirrhosis [11, 29, 51].
5.5 Treatment of bacterial cholangitis
Cholangitis occurs frequently but symptoms may be atypical. Prophylactic anti-
biotics should be ordered prior to and following biliary interventions. Positive bac-
terial or fungal cultures of bile can be associated with worse prognosis. Sometimes 
patients with recurrent cholangitis require long-term, rotating antibiotics.
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